Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DEGARELIX vs DELANDISTROGENE MOXEPARVOVEC-ROKL: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DEGARELIX vs DELANDISTROGENE MOXEPARVOVEC-ROKL: Safety Overview

Metric DEGARELIX DELANDISTROGENE MOXEPARVOVEC-ROKL
Total FAERS Reports 3,779 196
Deaths Reported 484 6
Death Rate 12.8% 3.1%
Hospitalizations 1,333 102
Average Patient Age 74.0 yrs 8.7 yrs
% Female Patients 0.7% 2.4%
FDA Approval Date Dec 24, 2008 N/A
Manufacturer Ferring Pharmaceuticals Inc. Sarepta Therapeutics, Inc.
Route N/A INTRAVENOUS
Marketing Status Prescription N/A